López-Soldado I, Niisuke K, Veiga C, Adrover A, Manzano A, Martínez-Redondo V, Camps M, Bartrons R, Zorzano A, Gumà A. Neuregulin improves response to glucose tolerance test in control and diabetic rats. Am J Physiol Endocrinol Metab 310: E440 -E451, 2016. First published December 29, 2015; doi:10.1152/ajpendo.00226.2015 is an EGFrelated growth factor that binds to the tyrosine kinase receptors ErbB3 and ErbB4, thus inducing tissue development and muscle glucose utilization during contraction. Here, we analyzed whether NRG has systemic effects regulating glycemia in control and type 2 diabetic rats. To this end, recombinant NRG (rNRG) was injected into Zucker diabetic fatty (ZDF) rats and their respective lean littermates 15 min before a glucose tolerance test (GTT) was performed. rNRG enhanced glucose tolerance without promoting the activation of the insulin receptor (IR) or insulin receptor substrates (IRS) in muscle and liver. However, in control rats, rNRG induced the phosphorylation of protein kinase B (PKB) and glycogen synthase kinase-3 (GSK-3) in liver but not in muscle. In liver, rNRG increased ErbB3 tyrosine phosphorylation and its binding to phosphatidylinositol 3-kinase (PI3K), thus indicating that rNRG activates the ErbB3/PI3K/PKB signaling pathway. rNRG increased glycogen content in liver but not in muscle. rNRG also increased the content of fructose-2,6-bisphosphate (Fru-2,6-P 2), an activator of hepatic glycolysis, and lactate in liver but not in muscle. Increases in lactate were abrogated by wortmannin, a PI3K inhibitor, in incubated hepatocytes. The liver of ZDF rats showed a reduced content of ErbB3 receptors, entailing a minor stimulation of the rNRG-induced PKB/GSK-3 cascade and resulting in unaltered hepatic glycogen content. Nonetheless, rNRG increased hepatic Fru-2,6-P 2 and augmented lactate both in liver and in plasma of diabetic rats. As a whole, rNRG improved response to the GTT in both control and diabetic rats by enhancing hepatic glucose utilization.
and the stress-inducible p38 MAPK, to regulate cell proliferation, survival, migration, and differentiation (54) . Transgenic mice for NRG or its ErbB receptors highlight the relevance of NRG for neuronal and cardiac development and function (19, 32, 36) .
Expressed by cells of endothelial, mesenchymal, and neuronal origin, most NRG isoforms contain one transmembrane domain (16) . The NRG EGF-like domain, which is required for ErbB receptor activation, is located extracellularly and released to the extracellular matrix by controlled proteolysis (22, 34, 37, 46) to bind ErbB receptors.
NRG acts locally in an autocrine and/or paracrine manner. However, this growth factor is also present in the blood, and it has been proposed as a biomarker for cardiovascular pathologies such as chronic heart failure (31), coronary artery disease, and ischemia (20) as well as for acute lung injury (15) in humans. In addition, in vivo administration of a bioactive recombinant NRG has been used therapeutically not only in mouse models of muscular dystrophy (30) , spinal cord injury (52), Parkinson's disease (5) , diabetic cardiomyopathy (33) , and myocardial infarction (1, 27) but also in patients with chronic heart failure (18, 28) . In all cases, this treatment was observed to ameliorate such pathological stages by protecting cells from degeneration and inducing proliferation. Recently, it has been proposed that ErbB2, acting as a coreceptor for NRG-1, is required for cardiomyocyte regeneration after myocardial infarction in mice (12) .
NRG is also involved in the regulation of glucose metabolism and insulin sensitivity in muscle (24) . It rapidly induces glucose uptake in skeletal muscle cell cultures and tissue in an insulin-independent manner by recruiting glucose transporters to the plasma membrane (49) . NRG is released by muscle during contraction in a calcium-and metalloprotease-dependent manner (3) . This effect of NRG appears to be local since an acute bout of exercise does not change serum NRG-1␤ levels for 30 min (38) . The inhibition of muscle ErbB4 receptors by blocking antibodies abrogates 50 -75% of the contraction-induced glucose uptake in skeletal muscle and also impedes the recovery of glycogen and ATP content (3) . These observations thus indicate the physiological relevance of muscle NRG on the rapid metabolic adaptation to contraction.
Type 2 diabetes is characterized by hyperglycemia, a condition caused by insulin resistance of the tissues targeted by this hormone, namely muscle, liver, and adipose tissue (13) . Many efforts have been devoted to elucidating this complex pathology as well as finding effective therapies to bypass defects in insulin action. A recent report (51) indicates that NRG-4, which is expressed mainly by brown and white adipose tissue, has distal effects on hepatic metabolism, reducing lipogenesis and protecting against diet-induced insulin resistance. Here, we studied the systemic effects of in vivo NRG administration in control and diabetic rats. We report that a bioactive recombinant NRG rapidly improves body response to a glucose tolerance test without altering the activation of the insulin receptor in skeletal muscle or in liver of control and diabetic rats. In control rats, rNRG increases hepatic glucose utilization by inducing the PI3K/PKB pathway, which is unaltered in skeletal muscle, whereas diabetic rats show resistance to NRG action. Animals. Animal studies were approved by the Ethics Committee of the University of Barcelona. Six-week-old male fa/fa Zucker diabetic fatty (ZDF) rats and their respective Zucker control lean (ZCL) fa/ϩ littermates were purchased from Charles River Laboratories (Wilmington, MA).
METHODS

Materials
Rats received Teklad Diet 2014 from Harlan (Indianapolis, IN) and had access to water ad libitum. The animals were kept in an environmentally controlled room under a 12-h light-dark cycle.
At 10 to 12 wk of age, ZDF rats were more obese than ZCL control counterparts (346 Ϯ 6 vs. 291 Ϯ 3 g body wt, respectively) and showed basal hyperglycemia under fasted conditions (6.4 Ϯ 0.4 vs. 3.4 Ϯ 0.2 mmol/l, respectively). Similarly, ZDF animals presented hyperinsulinemia under fasted conditions compared with ZCL rats (638 Ϯ 104 vs. 20 Ϯ 2 pmol/l, respectively). For the in vivo NRG treatment, rats were fasted overnight and then injected intraperitoneally (ip) with a solution of rNRG (17.8 g/ml) in saline at a dose of 25 g/kg rat body wt. The dose of rNRG administered was in the range of that used in other studies in rodents (1-10 g/kg) (28, 30, 33) and reached a concentration of 3-8 nM considering a mixing distribution space in fluids and tissues of Յ0.3-1 ml/g, to which in vitro effects on muscle glucose uptake were reported previously (49) . Untreated control groups received an equivalent amount of saline.
For the glucose tolerance test (GTT), a solution of glucose in saline (30 g/100 ml) was injected ip into fasted rats 15 min after rNRG/saline administration at a dose of 2 g/kg. Blood was extracted before (0 min) and after the glucose injection (15, 30, 60 , and 120 min). At 15 min, muscle and liver were dissected from rats anesthetized with isofluorane to analyze rNRG effects on signaling pathways and metabolism.
For insulin tolerance tests (ITTs), rats fasted for 6 h were injected ip with insulin (ZCL: 1.5 U/kg; ZDF: 2.0 U/kg) 15 min after rNRG/saline administration, and glycemia was measured from tail blood taken at the indicated times after injection (15, 30 , and 60 min).
Cell incubation. Suspensions of isolated hepatocytes from 24-hstarved ZCL and ZDF rats (12 wk of age) were prepared as indicated (35) . Cells were suspended in Krebs-Ringer bicarbonate buffer (pH 7.4) in the presence or absence of 20 mM glucose at 37°C with continuous shaking and gassed with carbogen (O 2-CO2, 19:1) throughout the incubation period. Hepatocytes (6 ml, 2.5 ϫ 10 6 cells/ml) were incubated in the absence or presence of wortmannin [2 M in dimethyl sulfoxide (DMSO)] for 15 min. Control cells were incubated in 0.2% (vol/vol) DMSO. Corresponding cells were then treated with recombinant neuregulin (3 nM) for 30 min. At the end of the experiments, the content of the incubated vials was centrifuged at 3,000 g for 1 min, and cell pellets were immediately frozen.
Measurement of blood metabolites. Blood glucose was determined in an Accu-Chek glucose monitor (Roche Diagnostics). Plasma was obtained from the extracted blood by centrifugation (1,650 g, 20 min) at 4°C and stored at Ϫ20°C until assayed. Plasma insulin was determined with the Ultrasensitive Rat Insulin ELISA kit (Mercodia, Uppsala, Sweden), and plasma lactate was determined spectrophotometrically using a commercial kit (Horiba, Montpellier, France).
Obtention of total lysates from muscle, liver, and incubated hepatocytes. For total lysates, pellets of incubated hepatocytes or 100 mg of frozen gastrocnemius or liver samples were homogenized as described before (4, 49) .
Immunoprecipitation and Western blots. To identify the tyrosine phosphorylation levels of IR␤, IRS-1, IRS-2, ErbB3, and ErbB1 and the levels of IRS-1, IRS-2, and ErbB3 bound to the p85 regulatory subunit of the PI3K, total lysates were immunoprecipitated by conjugating 30 l of protein G-Sepharose beads with 2-5 g of the corresponding polyclonal antibody for 1 h at 4°C. The beads were then washed twice in lysis buffer (4, 49) and incubated with 0.5-1 mg of protein lysate for 90 min with constant shaking at 4°C. After brief centrifugation, the supernatant was discarded. The pellet was washed several times with the lysis buffer and boiled for 5 min with 50 l of Laemmli sample buffer for Western blot analysis using a monoclonal anti-phosphotyrosine antibody or polyclonal p85-PI3K antibody. To identify the threonine phosphorylation levels of PKC/, total lysates were immunoprecipitated with beads conjugated to total PKC antibody, and the Western blot analysis was performed with an anti-phospho-Thr 410/403 -PKC/ antibody. For Western blot assays, immunoprecipitated samples were subjected to SDS-PAGE and transferred to PVDF membranes, as described previously (4) . Total lysates were used for immunoblot detection of IR␤, IRS-1, IRS-2, p85-PI3K, total PKB, phospho-Ser 473 -PKB, phospho-Thr 308 -PKB, total PKC, total GSK-3, and phospho-Ser 9 -GSK-3. Determination of lactate from muscle, liver, and incubated hepatocytes. The intracellular concentration of lactate was measured from perchloric acid extracts of muscle and liver and in pellets of incubated rat hepatocytes using a spectrophotometric commercial kit method (Horiba).
Measurement of muscle and liver glycogen content. Tibialis muscle (20 -30 mg) was hydrolyzed in 250 l of 1 mol/l HCl by heating at 95°C for 2 h. The solution was then neutralized with 250 l of 2 mol/l NaOH. Liver samples (100 mg) were hydrolyzed in 30% KOH by heating at 100°C for 10 min and then precipitated with ethanol and neutralized with 5 N H2SO4. In both cases, the resulting free glycosyl units were assayed spectrophotometrically using a hexokinase-dependent assay, as described previously (21) .
Measurement of glucose 6-phosphate in liver. The intracellular concentration of glucose 6-phosphate (G-6-P) was measured from perchloric acid extracts of livers using a fluorimetric method, as described previously (55).
Analysis of fructose-2,6-bisphosphate levels in liver extracts.
For fructose-2,6-bisphosphate (Fru-2,6-P 2) analysis, frozen livers were homogenized in five volumes of 50 mmol/l NaOH. The homogenates were heated at 80°C for 10 min, cooled, and adjusted to a pH of 6 -7. After centrifugation at 15,000 g for 10 min, Fru-2,6-P 2 was quantified in the supernatants as described by Van Schaftingen et al. (50) .
RNA extracts from rat liver and quantitative RT-PCR. Total RNA was isolated from rat liver tissue with Trizol reagent and purified with RNeasy kit columns (Qiagen). RNA from each sample was then reverse-transcribed using SuperScript III reverse transcriptase (SuperScript First-Strand Synthesis System for RT-Q-PCR; Invitrogen, Barcelona, Spain). Quantitative real-time PCR (qPCR) tests were performed, following the standard protocol of the ABI Prism 7900 Detection System. The following primers were used: ErbB1 forward primer 5=-GCTGTGC-GATTTAGCAACAA-3=, reverse primer 5=-GGACAGCTCGGATCA-CATTT-3=; ErbB2 forward primer, 5=-CGGAGGGAGAGTGGAT-GTTA-3=, reverse primer 5=-CAAGGAGGAGCTGT; ErbB3 forward primer 5=-TGGAATCCTAGGTGCCAAAG-3=, reverse primer 5=-TT-GCTCATCAACACCTCTGC-3=; ErbB4 forward primer 5=-CCTTAACCCCTAGTGGCACA-3=, reverse primer 5=-GCCA-CAGGGATTTTCACAGT-3=; peptidylprolyl isomerase A (Ppia) forward primer 5=-AGCATACAGGTCCTGGCATC-3=, reverse primer 5=-GCTCATGCCTTCTTTCACCT-3=. Data were analyzed with the 2 ⌬⌬CT method, with Ppia used as endogenous control. Statistical analysis. Data are presented as means Ϯ SE. Unpaired or paired t-tests were used to compare two groups and two-way ANOVA, and Tukey's post hoc test was used to compare more than two groups.
RESULTS
NRG improved body response to the GTT.
To determine whether the in vivo administration of NRG affects the GTT, rNRG was injected ip into ZCL and ZDF rats 15 min before the test was performed. The large increase in blood glucose observed 15 min after glucose administration was significantly reduced by rNRG in control rats (Fig. 1A) . The area under the curve (AUC) corresponding to the GTT of ZCL rats was significantly lower (17% decrease in AUC) in the rNRG-treated animals (Fig. 1A) . When ZCL rats were treated with rNRG without glucose being administered, basal glycemia was not altered (data not shown). rNRG also improved the response to a GTT (18% decrease in AUC) in ZDF rats (Fig. 1A) . Paralleling the effects on glycemia, the plasma insulin concentration was also reduced by rNRG in control rats (Fig. 1B) ; however, no significant differences were found in ZDF rats, a model in which hyperinsulinemia is a characteristic feature (Fig. 1B) . Next, we analyzed the effects of NRG under an ITT to reach high insulin levels (Fig. 1C) . NRG significantly reduced glycemia during the ITT in control rats, whereas in ZDF rats the decrease in glycemia did not reach significance (Fig. 1C) .
NRG action on muscle and liver insulin signaling. Given that skeletal muscle is the major site of glucose disposal during the absorptive state (14), we initially tested whether rNRG activates the insulin receptor (IR)-dependent cascade in skeletal muscle of control and diabetic rats under absorptive conditions (15 min after glucose administration). rNRG (30 min) did not induce IR or IRS-1 tyrosine phosphorylation or the association of IRS-1 with the p85 subunit of PI3K in gastrocnemius muscles of lean and diabetic rats compared with saline-treated animals ( Fig. 2A) .
Since rNRG did not induce the IR/IRS1/PI3K axis in skeletal muscle under absorptive conditions, we analyzed whether rNRG targets this pathway in the liver, an organ that also has a major role in blood glucose homeostasis. Again, rNRG had no effect on the tyrosine phosphorylation of the IR or IRS-1 in the livers of control or diabetic rats (Fig. 2B) . However, rNRG significantly reduced tyrosine phosphorylation of IRS-2 as well as the level of p85-PI3K bound to IRS-1 and IRS-2 in the livers of lean and diabetic rats (Fig. 2B) .
In accord with the lack of rNRG effect on the IR/IRS/PI3K pathway, rNRG did not increase PKB phosphorylation in skeletal muscle (Fig. 3A) , although it significantly induced Thr 410 /PKC phosphorylation, as reported previously (4), thereby indicating that this tissue responds to the administered rNRG. Surprisingly, rNRG increased PKB phosphorylation in the liver (Fig. 3B) . These results suggest that rNRG increases PKB activation without altering the IR, specifically in the liver. To further confirm these observations, we analyzed the phosphorylation of GSK-3, a PKB substrate. Indeed, whereas rNRG did not alter GSK-3 phosphorylation in muscle, its phosphorylation increased in the liver similarly to that of PKB (Fig. 3, A and B) . Intriguingly, the increase in PKB serine/threonine phosphorylation under rNRG action was significantly lower in the livers of diabetic than in control rats, and the effect on GSK-3 phosphorylation was totally impaired in diabetic rats. According to these results, NRG rapidly induces downstream insulin-like signaling pathway in liver, but not in muscle, in a manner totally independent of the IR pathway. Diabetic rats showed resistance to NRG.
Early NRG signaling cascade in the liver. Here, we analyzed whether rNRG induces a singular signaling cascade in the liver. It has been described that adult liver expresses NRG receptor ErbB3 and the EGF receptor ErbB1, whereas ErbB2 expression is lost during liver development (8, 9) . Initially, we determined ErbB receptor expression in liver by real-time PCR in ZCL and ZDF rats treated or not with rNRG. Relevant levels of ErbB1 and ErbB3 transcripts were measured, whereas ErbB2 mRNA was hardly detectable, and ErbB4 mRNA was not detected (Fig. 4A) . In control rats, rNRG induced the tyrosine phosphorylation of ErbB3 but not ErbB1 (Fig. 4B) . It has been reported previously that tyrosine-phosphorylated ErbB3 recruits PI3K (7, 26) . Phosphorylated ErbB3 contains six docking sites that bind to p85-PI3K SH 2 domains, conferring the receptor with a greater number of such sites. rNRG increased the binding of the p85 subunit of PI3K to ErbB3 in control rats (Fig. 4B) . The PI3K inhibitor wortmannin impaired rNRG-stimulated PKB phosphorylation in incubated hepatocytes (Fig. 5, A and B) . The levels of ErbB3 phosphorylation and binding to PI3K under rNRG action were lower in diabetic rats than in control animals (Fig. 4B) , an observation consistent with the lower PKB phosphorylation observed in the former (Figs. 3B and 5, A and B) . In this regard, we found that the liver of diabetic rats showed a lower ErbB3 and ErbB1 protein content than lean rats (Fig. 4B) , which may explain the lower activation of the PI3K/PKB pathway. Interestingly, we also observed that liver expressed NRG and that this expression was significantly higher in diabetic rats (Fig. 4B) . The higher NRG expression could be a compensatory response for the deficient ErbB receptor expression that shows the liver of diabetic rats.
Metabolic effects of NRG in the liver. To determine whether rNRG stimulates glucose utilization in the liver, we analyzed the levels of G-6-P and the hepatic 6-phosphofructo 1-kinase (PFK-1) allosteric activator Fru-2,6-P 2 (44, 53) . rNRG did not induce G-6-P accumulation (Fig. 6A) , but it induced significant increases in Fru-2,6-P 2 levels in the livers of both control and diabetic rats (Fig. 6B) . We also explored whether rNRG increases glycogen content in liver. Indeed, rNRG had rapid effects, doubling the amount of liver glycogen in control rats. In contrast, no significant increases were observed in liver of diabetic rats, maintaining a large amount of glycogen (25-to 50-fold higher than in control rats) even after 16 h of fasting (Fig. 6C) . Skeletal muscle glycogen content was not affected by the rNRG treatment in control ZCL or ZDF rats (Fig. 6C) . We measured lactate levels in liver and muscle. rNRG increased lactate content in the liver of control and diabetic rats but did not alter its levels in skeletal muscle (Fig.  6D) . Although no increase in plasma lactate was observed in rNRG-treated control rats, a significant increase was detected in diabetic ZDF rats after rNRG injection. This observation may indicate an increase in glucose flux through glycolysis in diabetic rats compared with the control ones (Fig. 6D) . These rNRG effects occurred without the expression of the glucose transporter GLUT2 being altered in the liver (data not shown). Studies in incubated hepatocytes indicated that the increased lactate content induced by rNRG was abrogated by wortmannin (Fig. 6E) .
DISCUSSION
Here, we show that the in vivo administration of rNRG rapidly improves glucose tolerance in response to both the GTT and ITT in control rats. At the doses used in our study (25 g/kg), rNRG did not alter basal glycemia in rats, although in swine it has been described that higher doses (2 mg/kg) may induce a transient hypoglycemic effect (17) . Diabetic rats also showed an improved GTT profile in response to acute rNRG action without the characteristic hyperinsulinemic state being altered. This observation indicates that rNRG alleviates insulin resistance or alternatively acts through an insulin-independent pathway. Here, we show that rNRG did not cause any change in IR phosphorylation in muscle or liver. The lack of an effect of rNRG on the IR has been reported previously in in vitro studies with muscle cells and tissue (3, 4) . The potent rNRG Open bars indicate ZCL rats in the absence of rNRG, dark gray bars ZCL rats in the presence of rNRG, black bars ZDF rats in absence of rNRG, and light gray bars ZDF in the presence of rNRG. B: total protein lysates were obtained and analyzed by Western blot. Representative images and quantification graphs of ErbB3 and ErbB1 tyrosine phosphorylation and PI3K bound to ErbB3, as well as ErbB3, PI3K, ErbB1, and NRG abundance, were measured in liver total protein extracts from ZCL and ZDF rats. ␣-Tubulin was used as a protein-loading control. Open bars indicate ZCL rats and black bars ZDF rats. Graph data are expressed as means Ϯ SE (n ϭ 5). *Statistical differences (P Ͻ 0.05) by 2-way ANOVA between the absence and presence of rNRG in ZCL and ZDF rats; #statistical differences (P Ͻ 0.05) by unpaired t-test between ZCL and ZDF rats. effect on PKB phosphorylation, observed selectively in the liver, contrasts with the lack of action on PKB observed in skeletal muscle and confirms a previous report in incubated muscle (4) . This observation may explain the scarce capacity of this growth factor to increase glucose uptake in resting muscle when compared with contracting muscle, a situation in which NRG is clearly involved (4). Such a distinct effect of rNRG on PKB in liver and muscle could result from differences in the early events of the NRG pathway in each tissue. Indeed, these two tissues show differences in the expression pattern of NRG receptors. Although ErbB4 is essentially involved in NRG promotion of glucose uptake during skeletal muscle contraction (3), its expression is barely detected in liver, where ErbB3 is the main NRG receptor (2, 9). Compared with ErbB4, ErbB3 has limited, if any, tyrosine kinase activity (47) , and thus the presence of a coreceptor is essential to drive intracellular signaling. Although ErbB2 is the preferred dimerization partner for ErbB3, it is lost during hepatic development, being undetectable in adult liver (2, 10) . However, the increase in ErbB1 expression during the postnatal period renders a new partner for ErbB3 (10) . Our studies confirmed the prevalence of ErbB1 and ErbB3 expression, both at the mRNA and protein level, in adult liver. Therefore, our results showing that rNRG induces hepatic ErbB3 tyrosine phosphorylation may indicate that, in response to rNRG, ErbB3 heterodimerizes and activates ErbB1 tyrosine kinase, whereas ErbB1 is not phosphorylated, as expected by the null-ErbB3 kinase activity.
In liver, rNRG administration generated a decrease in PI3K association with IRS-1 and IRS-2, which was concomitant with increased PI3K binding to phosphorylated ErbB3. Thus com- petition was established between IRS and ErbB3 for PI3K recruitment to their respective signaling cascades, and at the rNRG doses used in this study, phosphorylated ErbB3 receptors recruited PI3K more efficiently than phosphorylated IRS-1/IRS-2.
Since both insulin and rNRG activate a PI3K/PKB signaling pathway in the liver, it is feasible that, in a physiological context, neither effector acts simultaneously but that they compensate one another. At the expression level, it has been observed that insulin reduces the action of NRG in the liver. Whereas NRG increases ErbB3 protein synthesis (9), insulin suppresses ErbB3 expression (8, 9) in cultured rat hepatocytes. It is interesting to note that our diabetic model, characterized by sustained hyperinsulinemia, showed a lower protein content of both ErbB1 and ErbB3 receptors in the liver, which is in accord with the above-mentioned observations. Adult rat liver shows a circadian rhythm of ErbB3 expression and to a minor extent also of ErbB1, which increases by the end of the resting nonfeeding period when insulinemia reaches its lowest level, just before the animals become active and feed (10) . Moreover, hepatic ErbB3 expression increases substantially in two models of in vivo insulin deficiency, namely 48-h fasting and experimental streptozotocin-induced diabetes (8) . Notably, using antibodies that specifically recognize the characteristic signature of the EGF domains of all NRG isoforms, here we report that the liver endogenously expresses NRG. The finding that NRG expression increased significantly in diabetic rats, although it failed to sustain ErbB receptor expression, points to the alteration of the positive feedback between NRG and ErbB receptors in the liver in diabetes and the involvement of hyperinsulinemia in this alteration. Whether deficient hepatic NRG function contributes to the manifestation of diabetes remains to be determined. It is also unknown whether a higher NRG expression is contributing to the downregulation of IR expression that is observed in liver (48) in insulin resistance.
The activation of PKB is involved in the hepatic metabolic utilization of glucose. Thus, mammalian target of rapamycin complex 2 is responsible for PKB Ser 473 phosphorylation.
Using a liver-specific knockout, it has been established that PKB contributes to insulin-induced hepatic glycolysis (25). 6-Phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFKFB) is responsible for Fru-2,6-P 2 synthesis and breakdown. Fru-2,6-P 2 allosterically activates PFK-1 and glycolysis (40, 44) . The concentration and activity of PFKFB is higher in diabetic than in lean control animals, which might explain the higher concentration of Fru-2,6-P 2 observed in the former (41) . In the heart, PKB is required for the insulin-triggered activation of PFKFB (43) by inducing specific phosphorylation at Ser 483 , which increases its kinase activity, Fru-2,6-P 2 content, and consequently, lactate concentration (39) . The contribution of PKB to Fru-2,6-P 2 content in the liver remains to be determined. Furthermore, rNRG activation of the PKB-GSK-3 axis may be relevant for the increase in hepatic glycogen synthesis in control rats, as demonstrated previously for insulin action (11, 45) . The deficient NRG-dependent activation of the PKB/GSK-3 axis and already sizable glycogen pool in diabetic rats may explain the unaltered hepatic glycogen content and the increase in plasma lactate levels in these animals. Additionally, diabetic animals treated with rNRG continued to show higher levels of Fru-2,6-P 2 and lactate in the liver, indicating that hepatic glycolysis was further potentiated, thereby contributing to maintain glucose utilization.
Here, we provide the first evidence indicating that NRG improves the response to the glucose tolerance test in both control and diabetic rats by enhancing hepatic glucose utilization (Fig. 7) . Our results also suggest that, although it is an essential factor in the stimulation of glucose uptake during muscle contraction, NRG does not target muscle metabolism during absorptive conditions. The resistance to NRG observed in the liver of diabetic rats may be caused by a variety factors in which hyperinsulinemia may play a relevant role by reducing ErbB3 expression as an initiating factor.
LIVER ErbB1
ErbB3 Fig. 7 . Scheme on the proposal for NRG action inducing hepatic glucose utilization. PFKFB, 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase; PFK-1, 6-phosphofructo 1-kinase.
